Intensity Therapeutics, Inc.

INTS chart

Intensity Therapeutics, Inc. news

• Investigation continues into Duketon gold project incident

  Safe To Work · Nov 9, 5:49 PM EST

• Weekly Recap: Q3 loss and cash position and StoneX lowers price target

  TradingView · Nov 9, 6:00 AM EST

• H.C. Wainwright Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $7

  Moomoo · Nov 6, 2:31 PM EST

• StoneX maintains Intensity Therapeutics at Speculative Buy, lowers price target to $8 from $12

  TradingView · Nov 6, 9:04 AM EST

• Intensity (INTS) Q3 2026 Earnings Call Transcript

  fool.com · Nov 5, 5:28 PM EST

• Intensity Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

  TradingView · Nov 5, 11:14 AM EST

• Intensity Therapeutics Q3 Loss Widens as Trial Enrollment Resumes

  Securities.io · Nov 5, 9:53 AM EST

• Intensity Therapeutics Q3FY26 Results: Net loss widens to $3.5 million

  scanx.trade · Nov 5, 9:07 AM EST

• Intensity Therapeutics Q3 2026 Earnings Call Transcript

  Benzinga · Nov 5, 8:47 AM EST

• Intensity Therapeutics, Inc. (INTS) Misses Q3 EPS by 13c

  StreetInsider · Nov 5, 8:47 AM EST

• Form 8K Intensity Therapeutics Inc For: 5 November By Investing.com

  Investing.com Canada · Nov 5, 8:37 AM EST

• Intensity Therapeutics Reports Q3 2026 Results, $8.5 Million in Cash

  TradingView · Nov 5, 8:03 AM EST

Intensity Therapeutics, Inc. key financials

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 8-K8-K2026-11-05
• 10-Q10-Q2026-11-05
• 8-K8-K2026-08-11
• 10-Q10-Q2026-08-11
• 8-K8-K2026-06-16
• 8-K8-K2026-05-07
• 10-Q10-Q2026-05-07
• DEF 14ADEF 14A2026-04-30
• 8-K8-K2026-03-27
• 10-K10-K2026-03-27
• 8-K8-K2026-03-23
• 8-K8-K2026-03-06

About Intensity Therapeutics, Inc.

Ticker

INTS (Nasdaq)

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Shelton, CT

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

1567264

Frequently asked questions